Abstract
Background: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.
Methods: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.
Results: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.
Conclusions: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.
Keywords: COVID-19; SARS-CoV-2; common variable immunodeficiency; monoclonal antibodies; primary antibody deficiencies.
【저자키워드】 COVID-19, SARS-CoV-2, monoclonal antibodies, common variable immunodeficiency, primary antibody deficiencies., 【초록키워드】 Treatment, coronavirus disease, Efficacy, coronavirus, therapy, Prospective Study, monoclonal antibody, Antiviral effect, Clinical outcome, qPCR, Patient, Quantitative, mAbs, monoclonal, mAb, administration, Standard of care, acute respiratory syndrome, deficiencies, effective, primary antibody, polymerase chain, conducted, added, patients treated, SARS-CoV-2-infected patient, 【제목키워드】 coronavirus 2, respiratory,